The therapeutic landscape of advanced urothelial cancer has undergone a significant transformation in recent years with the addition of PD-1/PD-L1 targeting immune checkpoint inhibitors and novel antibody-drug conjugates to the treatment armamentarium. In this Clinical Insights on the Treatment Algorithm in Unresectable Locally Advanced or Metastatic Urothelial Cancer, experts in the field will discuss the latest evidence supporting the use of these therapies in clinical practice, including patient selection for cisplatin/carboplatin eligible and platinum ineligible and optimal treatment strat ..read more

There is a steadily widening range of second-line (2L) and subsequent treatment options for patients with advanced UC including chemotherapy, immune checkpoint inhibitors (ICIs) and novel therapies. In recent years, ICIs have predominantly replaced chemotherapy as the preferred 2L treatment. Furthermore, antibody-drug conjugates (ADC) and targeted agents have become available. The selection of 2L and salvage treatments for advanced UC depends on many factors, including the initial treatment strategy used in the first-line setting. Molecular classifications appear to be promising in disease pro ..read more

About 70% to 80% of bladder cancers present as non-muscle-invasive bladder cancer (NMIBC). The management of NMIBC includes transurethral resection of bladder tumor (TURBT), followed by single-dose intravesical immunotherapy with bacille Calmette-Guérin (BCG) or intravesical chemotherapy (mitomycin C, epirubicin, or doxorubicin). The decision to instill BCG and/or chemotherapy is based on the risk of cancer progression or recurrence. For practicing oncologists, it is crucial to address Frequently Asked Questions (FAQs) regarding NMIBC such as how to define individual risk groups and treatment ..read more

Platinum-based chemotherapy (CT) has been the preferred treatment for patients with unresectable locally advanced and/or metastatic (LA/m) urothelial cancer (UC) for several decades. With the evolving development of immunotherapy in the first-line (1L) setting, the standard management approach for LA/m UC consisted of cisplatin-based CT in cisplatin eligible patients or carboplatin-based CT in cisplatin ineligible patients followed by maintenance avelumab (an anti-PD-L1 inhibitor) in those who do not have disease progression with 1L platinum-based CT. However, with the release of EV-302 and C ..read more

In the first of three podcasts exploring the role of immunotherapy in advanced urothelial cancer, genitourinary cancer experts Dr Tom Powles and Dr Aristotelis Bamias discuss the latest evidence-based treatment strategies for patients with advanced metastatic urothelial cancer.  ..read more

In this episode, the experts assess the latest data on targeted therapy for KRAS G12C-mutated NSCLC, including the first phase III data on targeted therapy. Hear expert opinions of how these results may influence clinical practice.   ..read more

Recent advances in genomic profiling technology have led to the identification of several rare actionable alterations in advanced NSCLC; targeted therapies for many of these molecular NSCLC subtypes are now available. In this episode, the experts evaluate the latest updates from clinical trials using these agents and the impact on clinical practice.  ..read more

In this episode, the experts discuss the latest insights on osimertinib resistance in EGFR-mutated NSCLC and promising new data on targeting MET amplification, one of the most common acquired resistance mechanisms to first-line osimertinib ..read more

In this episode, lung cancer experts discuss the treatment approach for patients with early-stage, resectable NSCLC who  harbor EGFR sensitizing mutations. Listen to the latest clinical trial data on the use of adjuvant targeted therapy for this patient population ..read more

In this episode, experts explore new data related to EGFR TKI resistance, specifically resistance to osimertinib. Listen to our experts evaluating the real-world data on most common resistance mechanisms to osimertinib and emerging strategies to overcome resistance.  ..read more